BeyondSpring (BYSI) Competitors $1.68 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.03 (+1.49%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends BYSI vs. DMAC, AVIR, CRVS, RZLT, SLRN, ACIU, SOPH, YMAB, SEPN, and CMPSShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include DiaMedica Therapeutics (DMAC), Atea Pharmaceuticals (AVIR), Corvus Pharmaceuticals (CRVS), Rezolute (RZLT), Acelyrin (SLRN), AC Immune (ACIU), SOPHiA GENETICS (SOPH), Y-mAbs Therapeutics (YMAB), Septerna (SEPN), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. DiaMedica Therapeutics Atea Pharmaceuticals Corvus Pharmaceuticals Rezolute Acelyrin AC Immune SOPHiA GENETICS Y-mAbs Therapeutics Septerna COMPASS Pathways DiaMedica Therapeutics (NASDAQ:DMAC) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends. Do insiders & institutionals believe in DMAC or BYSI? 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 7.2% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate DMAC or BYSI? DiaMedica Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 12.72%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in DMAC or BYSI? BeyondSpring received 92 more outperform votes than DiaMedica Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 62.84% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% BeyondSpringOutperform Votes18566.79% Underperform Votes9233.21% Is DMAC or BYSI more profitable? BeyondSpring's return on equity of 0.00% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% BeyondSpring N/A N/A N/A Which has more volatility and risk, DMAC or BYSI? DiaMedica Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Does the media refer more to DMAC or BYSI? In the previous week, DiaMedica Therapeutics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for DiaMedica Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat DiaMedica Therapeutics' score of 0.30 indicating that BeyondSpring is being referred to more favorably in the news media. Company Overall Sentiment DiaMedica Therapeutics Neutral BeyondSpring Very Positive Which has preferable earnings and valuation, DMAC or BYSI? DiaMedica Therapeutics has higher earnings, but lower revenue than BeyondSpring. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-11.09BeyondSpring$1.88M34.95-$21.03MN/AN/A SummaryBeyondSpring beats DiaMedica Therapeutics on 8 of the 14 factors compared between the two stocks. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.57M$7.21B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E RatioN/A6.1524.9519.24Price / Sales34.95187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book-1.856.447.334.28Net Income-$21.03M$139.03M$3.18B$247.04M7 Day Performance-2.33%-5.52%-4.42%-4.36%1 Month Performance-2.04%-8.56%-6.07%-5.60%1 Year Performance12.00%-14.59%11.42%3.38% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.68-0.6%N/A+12.7%$65.57M$1.88M0.0080Positive NewsDMACDiaMedica Therapeutics1.088 of 5 stars$6.25-4.0%$7.00+12.0%+112.7%$267.26MN/A-11.1620Short Interest ↑High Trading VolumeAVIRAtea Pharmaceuticals3.2346 of 5 stars$3.14+1.6%$6.88+119.1%-31.9%$265.20MN/A-1.5270CRVSCorvus Pharmaceuticals3.1199 of 5 stars$4.09-2.4%$12.38+202.6%+85.3%$262.81MN/A-4.4030News CoveragePositive NewsRZLTRezolute2.9058 of 5 stars$4.33-4.4%$24.38+462.9%+146.1%$262.10MN/A-3.5540Positive NewsSLRNAcelyrin3.2886 of 5 stars$2.58-0.8%$9.60+272.1%-68.9%$258.84MN/A-1.05135Short Interest ↓Positive NewsHigh Trading VolumeACIUAC Immune2.3908 of 5 stars$2.60-1.9%$12.00+361.5%-34.0%$257.24M$40.97M-5.65140SOPHSOPHiA GENETICS1.9613 of 5 stars$3.93-3.4%$7.40+88.3%-24.2%$256.94M$62.37M-3.61520Short Interest ↑YMABY-mAbs Therapeutics2.3304 of 5 stars$5.69-0.5%$20.89+267.1%-70.3%$254.85M$84.55M-10.54150Analyst ForecastNews CoverageSEPNSepterna2.4256 of 5 stars$5.73-1.2%$34.00+493.4%N/A$254.41MN/A0.00N/AUpcoming EarningsGap DownCMPSCOMPASS Pathways1.8363 of 5 stars$3.70-12.1%$30.60+727.0%-65.8%$253.15MN/A-1.68120Earnings ReportAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies DMAC Competitors AVIR Competitors CRVS Competitors RZLT Competitors SLRN Competitors ACIU Competitors SOPH Competitors YMAB Competitors SEPN Competitors CMPS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BYSI) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BYSI Stock Alerts